Trial Profile

An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-552 in Healthy Adult Japanese and Han Chinese Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV 552 (Primary)
Indications Alzheimer's disease; Cognition disorders
Focus Adverse reactions; Pharmacokinetics
Sponsors AbbVie

Most Recent Events

29 Mar 2024 Results assessing Pharmacokinetics, Safety and Tolerability of Abbv-552 in Healthy Adult Japanese and Han Chinese Subjects presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
04 Apr 2023 Status changed from active, no longer recruiting to completed.
03 Mar 2023 Planned End Date changed from 13 Apr 2023 to 30 Mar 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com